Pharma: Page 71
-
Adeline Kon/BioPharma Dive
Deep Dive // Brain drug revivalBig pharma backed away from brain drugs. Is a return in sight?
Biotech executives see a new era of neuroscience breakthroughs on the horizon. But in a historically challenging space, it's hard to pinpoint what would cause big pharma to dive back in — and what ripples that would create.
By Jacob Bell • Jan. 29, 2020 -
Zolgensma sales grow, signaling gene therapy momentum
Another 100 infants received Novartis' gene therapy in the fourth quarter, supported by broad insurance coverage and more newborn screening.
By Ned Pagliarulo • Jan. 29, 2020 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Pfizer lays out gene therapy aspirations
With more Phase 3 trials on the near horizon, the big pharma plans to add one new gene therapy project per year to its pipeline.
By Jonathan Gardner • Jan. 28, 2020 -
To close merger, AbbVie and Allergan sell digestive drug to AstraZeneca
Allergan acquired global rights to brazikumab for $250 million up front in 2016, but expected antitrust conflicts pushed it and AbbVie to pursue a divestment.
By Jonathan Gardner • Jan. 27, 2020 -
Pfizer hits its biosimilar stride
The big pharma, which has criticized other companies for stifling the U.S. biosimilars market, is now poised to launch three of these copycat biologics in as many months.
By Jacob Bell • Jan. 27, 2020 -
Ipsen pauses studies of drug for rare bone disease
The decision makes a mid-2020 approval and launch, which Ipsen expected when it acquired the drug, less likely.
By Jacob Bell • Jan. 24, 2020 -
Permission granted by Roche
Roche strengthens case for SMA drug with new study data
Results showed the oral drug can help improve motor function in babies with the severest form of a rare degenerative muscular disease.
By Jonathan Gardner • Jan. 23, 2020 -
Courtesy of Eli Lilly
Lilly to invest $470M in new North Carolina drug plant
The facility, which will employ more than 400, is part of a broader build-out by Lilly of its manufacturing network.
By Kristin Jensen • Jan. 22, 2020 -
5 biopharmas to watch as the decade's last earnings kick off
Biogen faces down analysts one more time on its aducanumab plans, while two biotechs could give early glimpses into their first-ever drug launches.
By Ned Pagliarulo , Jacob Bell • Jan. 21, 2020 -
Kendall Davis/BioPharma Dive
While expected, Intercept's approval delay adds to NASH uncertainty
An upcoming FDA advisory meeting will be a key test for Intercept's ambitions to become the first drugmaker with an approved therapy for the liver disease.
By Jacob Bell • Jan. 17, 2020 -
Lilly seeking out more 'Dermira-like' deals: report
The pharma is targeting deals between $1 billion and $5 billion every quarter, its CFO told Reuters, although the focus will be on clinical-stage assets.
By Jonathan Gardner • Jan. 17, 2020 -
Danielle Ternes/BioPharma Dive
Neuroscience's decade, a biotech's 'crown jewel,' and Ionis gets selective
Roche, maker of the last decade's top cancer drugs, is betting that neuroscience R&D can make strides in the 2020s — an outlook that contrasts with research retreats by the pharma's peers.
By Andrew Dunn , Jacob Bell • Jan. 15, 2020 -
Danielle Ternes/BioPharma Dive
Alexion's neuro bet, Rubius' trial troubles and biotech's gene therapy milestones
On the first day of the JPM conference, Alexion mapped out ambitious plans in neuroscience, while Rubius did its best to explain delays in testing its first drug.
By Jacob Bell , Andrew Dunn • Jan. 14, 2020 -
With UK partnership, Novartis plots ambitious plans for new heart drug
The Swiss pharma giant will work with U.K. health officials to run a primary prevention study of inclisiran, acquired last month via a $10 billion deal for The Medicines Co.
By Andrew Dunn • Updated Jan. 14, 2020 -
AbbVie to house Allergan Botox business in separate unit
Allergan's eyecare and specialty drugs, however, will be folded into the existing AbbVie organization once its $63 billion acquisition is complete.
By Jonathan Gardner • Jan. 8, 2020 -
Jacob Bell/BioPharma Dive
Merck's Keytruda falls short of rivals in 1 lung cancer type
Mixed results could put Merck at a disadvantage in small cell lung cancer, a tumor type which has proved responsive to Roche's Tecentriq and AstraZeneca's Imfinzi.
By Jonathan Gardner • Jan. 7, 2020 -
Retrieved from National Cancer Institute on September 27, 2019
Merck adds to lung cancer wall with Otsuka deal
The $50 million deal with two Japanese biotechs is a small bet to match challengers in Amgen and Mirati, who are advancing agents targeting KRAS mutations.
By Jonathan Gardner • Jan. 6, 2020 -
GSK's plan to take over the HIV drug market hasn't worked out
An FDA rejection and modest sales for two marketed products are challenging GSK's argument that two-drug treatments are a better way to treat HIV.
By Jacob Bell • Jan. 6, 2020 -
AstraZeneca and Merck's Lynparza cleared by FDA for pancreatic cancer
The pill is the second targeted treatment approved for pancreatic cancer, although its use is limited to only a small share of patients.
By Jonathan Gardner • Dec. 30, 2019 -
Permission granted by Roche
Roche hands $1B to Sarepta in major return to gene therapy deals
The Swiss pharma acquired a muscular dystrophy treatment for markets outside the U.S. in a pact that could reach a value of $10 billion.
By Jonathan Gardner • Dec. 23, 2019 -
Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals
AstraZeneca bet big on the Japanese pharma's HER2-targeting therapy, a gamble that paid off with a speedy approval for Enhertu.
By Jonathan Gardner • Updated Dec. 23, 2019 -
Jacob Bell/BioPharma Dive
AstraZeneca lupus drug shows potential, but it may not be enough for FDA
If approved, anifrolumab would compete against GlaxoSmithKline's Benlysta, the first lupus drug to reach the market in decades.
By Jonathan Gardner • Dec. 19, 2019 -
GSK advances blood cancer drug to FDA, but rivals threaten
Belantamb mafodotin, a crucial drug for GSK's ambitions in oncology, could be the first anti-BCMA therapy approved. But new data show it's at risk of being outclassed.
By Ned Pagliarulo • Dec. 17, 2019 -
Jonathan Gardner/BioPharma Dive
BeiGene's Brukinsa bet falls short against Imbruvica
The Chinese biotech's recently approved cancer drug wasn't able to beat out Imbruvica in a rare lymphoma, raising questions about its next regulatory filing.
By Jonathan Gardner • Dec. 16, 2019 -
Novartis still hasn't solved its CAR-T manufacturing issues
Lingering difficulties in making all Kymriah product to FDA specifications has meant Novartis can't always charge for the cell therapy. New data at ASH could help the pharma's case.
By Ned Pagliarulo • Dec. 11, 2019
Previous
